Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy

Journal of Endocrinological Investigation

Volumn 27, Issue 3, 2004, Pages 272-280

  Marcocci, Claudio ^a   Marino M ^a   Rocchi, R ^a   Menconi, F ^a   Morabito, E ^a   Pinchera, A ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Graves' ophthalmopathy; Immunosuppressive therapy; Orbital radiotherapy

Indexed keywords

ALLOPURINOL; ANGIOPEPTIN; ANTIOXIDANT; CYTOKINE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; NICOTINAMIDE; OCTREOTIDE; OXYGEN RADICAL; PENTOXIFYLLINE; PLACEBO; PREDNISONE; SOMATOSTATIN DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; COBALT THERAPY; CUSHINGOID SYNDROME; CYTOKINE PRODUCTION; DEPRESSION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; GASTRITIS; GLUCOSE INTOLERANCE; HEPATITIS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION; LIVER DYSFUNCTION; LIVER FAILURE; LONG TERM CARE; LOW DRUG DOSE; RETROSPECTIVE STUDY; REVIEW; THYROIDECTOMY; URINARY TRACT INFECTION;

EID: 2342664196     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345277     Document Type: Review

References (47)

1. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000, 21: 168-99.
2. Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study Instrument. Thyroid 1997, 7: 885-9.
3. Krassas GE, Heufelder AE. Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 2001, 144: 311-8.
4. Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous and oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001, 86: 3562-7.
5. Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000, 10: 521.
6. 111In-DTPA-D-Phe1) octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter of disease activity. J Clin Endocrinol Metab 1994, 79: 1845-51.
7. Kahaly G, Diaz M, Just M, Beyer J, Lieb W. Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy. Thyroid 1995, 5: 107-11.
8. Krassas KE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 1995, 42: 571-80.
9. 111In-diethylenetriamine pentaacetic acid-D-Phe-1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1998, 83: 3790-4.
10. Pasquali D, Notaro A, Bonavolontà G, Vassallo P, Bellastella A, Sinisi AA. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease. J Clin Endocrinol Metab 2002, 87: 5125-9.
11. Chang TC, Kao SCS, Huang KM. Octreotide and Graves' ophthalmopathy and pretibial mixedema. Br Med J 1992, 304: 158.
12. Kung AVC, Michon J, Tai KS, Chan FL. The effect of somatostatin versus corticosteroids in the treatment of Graves' ophthalmopathy. Thyroid 1996, 6: 381-4.
13. Krassas GE, Kaltsas T, Dumas A, Pontikides N, Tolis G. Lanreotide in the treatment of patients with thyroid eye disease. Eur J Endocrinol 1997, 136: 416-22.
14. Ratko TA, Burnett DA, Foulke GE and the University Hospital Consortium Expert Panel for Off-Label use of polyvalent Intravenously administered Immunoglobulin Preparation. Recommendations for off-label use of intravenously administered immunoglobulin preparation. JAMA 1995, 273: 1865-70.
15. Antonelli A, Saracino A, Alberti B, et al. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy. Acta Endocrinol (Copenh) 1992, 126: 13-23.
16. Baschieri L, Antonelli A, Nardi S, et al. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. Thyroid 1997, 7: 579-85.
17. Kahaly G, Pitz S, Muller-Forrell W, Hommel G. Randomized trial of intravenous immunoglobulin versus prednisolone in Graves' ophthalmopathy. Clin Exp Immunol 1996, 106: 197-202.
18. Seppel T, Schlaghecke R, Becker A, Engelbrecht C, Feldkamp J, Kornely E. High-dose intravenous therapy with 7S immunoglobulins in autoimmune endocrine ophthalmopathy. Clin Exp Immunol 1996, 14 (Suppl 15): S109-14.
19. Wiersinga WM, Prummel MF. Pathogenesis of Graves' ophthalmopathy-Current understanding. J Clin Endocrinol Metab 2001, 86: 501-3.
20. De Carli MM, Mariotti S, Marcocci C, et al. Cytolytic T cells with Th1-like profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab 1993, 77: 1120-4.
21. Bahn RS. Graves' ophthalmopathy: the role of cytokines in pathogenesis. In: Grass GH and Kaplan HM eds. Handbook of Endocrinology. 2nd ed. vol 1. Boca Rato: CRC Press. 1996, 287-95.
22. Smith TJ, Bahn RS, Gorman CA, Cheavens M. Stimulation of glycosaminoglycan accumulation by interferon γ in cultured retroocular fibroblasts. J Clin Endocrinol Metab 1991, 72: 1169-71.
23. Bartalena L, Marcocci C, Pinchera A. Cytokine antagonists: new ideas for the management of Graves' ophthalmopathy. J Clin Endocrinol Metab 1996, 81: 446-8.
24. Raza A. Anti-TNF therapies in rheumatoid arthritis, Chron's disease, sepsis, and myelodisplastic syndrome. Micr Res Techn 2000, 50: 229-35.
25. Tan GH, Dutton CM, Bahn RS. Interleukin-1 (IL-1) receptor antagonists and soluble IL-1 receptor inhibit IL-1-induced glycosamimoglycans production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1996, 81: 449-52.
26. Hofbauer LC, Muglberg T, Konig A, Heufelder G, Schworm H-D, Heufelder AE. Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves' ophthalmopathy undergoing orbital radiotherapy. J Clin Endocrinol Metab 1997, 82: 2244-7.
27. Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentration of proinflammatory cytokines in Graves' disease: effect of thyroid function, ophthalmopathy and sigarette smoking. Eur J Endocrinol 2000, 143. 197-202.
28. Bartalena L, Manetti L, Tanda ML, et al. Soluble interleukin receptor antagonist concentration is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids. Clin Endocrinol (Oxf) 2000, 52: 647-51.
29. Balazs C, Kiss E, Vamos A, Molnar I, Farid NR. Beneficial effect of pentoxyfilline on thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 1998; 82: 1999-2002.
30. Chang C-C, Chang T-C, Kao SCS, Kuo Y-F, Chien L-F. Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial myxoedema. Acta Endocrinol (Copenh) 1993, 129: 322-7.
31. Balazs C, Kiss H, Farid NR. Inhibitory effect of pentoxifylline on HLA-DR expression and glycosaminoglycan synthesis by retrobulbar fibroblasts. Horm Metab Res 1998, 30: 496-9.
32. Doerge DR, Taurog A, Dorris M. Evidence for a radical mechanism in peroxidase-catalyzed coupling. I. Steady-state experiments with various peroxidases. Arch Biochem Biophys 1994, 315: 82-9.
33. Venditti P, Balestrieri M, Di Meo S, De Leo T. Effect of thyroid state on lipid peroxidation, antioxidantd defences, and susceptibility to oxidative stress in rat tissues. J Endocrinol 1997, 155: 151-7.
34. Hiromatsu Y, Yang D, Miyake I, et al. Nicotinamide decreases cytokine-induced activation of orbital fibroblasts from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 1998, 83: 121-4.
35. Bouzas EA, Karadimas P, Mastrorakos G, Koutras DA. Anti-oxidant agents in the treatment of Graves' ophthalmopathy. Am J Ophthalmol 2000, 129: 618-22.
36. Marcocci, C, Bartalena, L, Pinchera, A. Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 1998, 21: 468-71.
37. Catz B, Perzik SL. Total thyroidectomy in the management of thyrotoxic and euthyroid Graves' disease. Am J Surg 1969, 118: 434-9.
38. DeGroot LJ. Evaluation of thyroid ablative therapy for ophthalmopathy of Graves' disease. Orbit 1996, 187-96.
39. Hildebrandt G, Seed MP, Freemantle CN, Alan CAS, Colville-Nash PR, Trott KR. Mechanisms of the anti-infiammatory activity of low-dose radiation therapy. Int J Radiat Biol 1998, 74: 367-78.
40. Kahaly G, Roesler HP, Pitz S, Hommel G. Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 2000, 85: 102-8.
41. Mourits MP, van Kempen-Harteveld, Garcia MBG, Koppeschaar HPF, Tick L, Terwee CB. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 2000, 355: 1505-9.
42. Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001, 108: 1523-4.
43. Gorman CA, Garrity JA, Fatourechi V, et al. The aftermath of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2002, 109: 2100-7.
44. Bartalena L, Marcocci C, Gorman CA, Wiersinga WM, Pinchera A. Orbital radiotherapy for Graves' ophthalmopathy: Useful or useless? Safe or dangerous. J Endocrinol Invest 2003, 26: 5-16
45. Marcocci C, Bartalena L, Marinò M, et al. Current medical management of Graves' ophthalmopahy. Ophthal Plast Reconstr Surg 2002, 18: 402-8.
46. Marcocci C, Bartalena L, Rocchi R, et al. Long term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 2003, 88: 3561-6.
47. Bartalena L. Smoking and Graves' disease. J Endocrinol Invest 2002, 25: 402.